A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach

Jorn Mulder 1*, Odile C. van Stuijvenberg 1, Paula B. van Henrikk 1, Emile E. Voest 2,3, Anna M. G. Pasmooij 1, Violeta Stoyanova-Beninska 1 and Anthonius de Boer 1,4

1 Dutch Medicines Evaluation Board, Utrecht, Netherlands, 2 The Netherlands Cancer Institute, Amsterdam, Netherlands, 3 Oncode Institute, Amsterdam, Netherlands, 4 Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

There are currently four anti-cancer medicinal products approved for a tissue-agnostic indication. This is an indication based on a common biological characteristic rather than the tissue of origin. To date, the regulatory experience with tissue-agnostic approvals is limited. Therefore, we compared decision-making aspects of the first tissue-agnostic approvals between the Food and Drug Administration (FDA), European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). Post-marketing measures (PMMs) related to the tissue-agnostic indication were of specific interest. The main data source was the publicly available review documents. The following data were collected: submission date, approval date, clinical trials and datasets, and PMMs. At the time of data collection, the FDA and PMDA approved pembrolizumab, larotrectinib, and entrectinib for a tissue-agnostic indication, while the EMA approved larotrectinib and entrectinib for a tissue-agnostic indication. There were differences in analysis sets (integrated vs. non-integrated), submission dates and requests for data updates between agencies. All agencies had outstanding issues that needed to be addressed in the post-market setting. For pembrolizumab, larotrectinib and entrectinib, the number of imposed PMMs varied between one and eight, with the FDA requesting the most PMMs compared to the other two agencies. All agencies requested at least one PMM per approval to address the remaining uncertainties related to the tissue-agnostic indication. The FDA and EMA requested data from ongoing and proposed trials, while the PMDA requested data from use-result surveys. Confirmation of benefit in the post-marketing setting is an important aspect of tissue-agnostic approvals, regardless of agency. Nonetheless, each approach to confirm benefit has its inherent limitations. Post-marketing data will be essential for the regulatory and clinical decisions-making of medicinal products with a tissue-agnostic indication.

Keywords: FDA, EMA, PMDA, tissue-agnostic indication, post-marketing measures
INTRODUCTION

On May 23, 2017, the Food and Drug Administration (FDA) approved for the first time a medicinal product for a tissue-agnostic indication, i.e., an indication based on a common biological characteristic rather than the tissue of origin (1). This approval concerned pembrolizumab for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors. During the following years, the FDA approved three other medicinal products for a tissue-agnostic indication and pembrolizumab for an additional tissue-agnostic indication (2–5). The European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA), as well as other agencies, also recommended approval for medicinal products for a tissue-agnostic indication. These recommendations resulted in approvals granted by the European Commission (EC) and the Japanese Ministry of Health, Labor and Welfare (MHLW), respectively.

Pembrolizumab for the treatment of MSI-H/dMMR solid tumors was granted ‘accelerated approval’ by the FDA (1). Accelerated approval is based on an effect on a surrogate endpoint that is likely to predict clinical benefit (6). For this type of approval, the drug developer is obligated to provide additional data in the post-marketing setting to confirm clinical benefit. Hence, confirmatory data will be expected for pembrolizumab for the abovementioned indication. To accommodate similar cases, the EMA also established – years ago – an expedited approval pathway comparable to that of the FDA called “conditional marketing authorization.” Conditional marketing authorization is based on less comprehensive data than normally required (7). Importantly, both expedited programs are developed to address an unmet medical need (6, 7).

As there are currently few tissue-agnostic approvals, regulatory experience is limited. The EMA and PMDA have issued guidance documents that include information on master protocol designs and the registration of medicinal products for tissue-agnostic indications (8, 9). Another relevant document is the FDA guidance for industry on developing targeted therapies in low-frequency molecular subsets of a disease (10). However, detailed information on data requirements for tissue-agnostic approvals or how to confirm the tissue-agnostic indication in the post-marketing setting is currently not available. Therefore, we believe that evaluation of the first tissue-agnostic approvals will allow to better define the requirements for this type of indication.

The main purpose of our study was to compare decision-making aspects of the first tissue-agnostic approvals between regulatory agencies. We were specifically interested in the post-marketing measures (PMMs) imposed to resolve outstanding issues related to the tissue-agnostic indication, and whether these PMMs were different between regulatory agencies. Other aspects of interest were the datasets supporting each approval and the submission and approval dates. We limited our research to the founding regulatory members of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, i.e., the FDA, EMA and PMDA.

METHODS

Data Sources

The primary data source was the publicly available review documents. These included the Multi-Discipline Reviews from the FDA, the European Public Assessment Reports (EPARs) from the EMA, and the Review Reports from the PMDA. Other documents used in this study were the Approval Letters from the FDA, Summary of Product Characteristics (SmPCs) from the EMA, and the List of Approved Products from the PMDA. Review documents are available at the website of each respective agency. Review documents are available at: https://www.ema.europa.eu/en/medicines, https://www.accessdata.fda.gov/scripts/cder/daf/, and https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html.

Data Collection

The following data were collected from the review documents: submission date, approval date, (pivotal) clinical trials, clinical datasets, and PMMs. For procedures reviewed by the EMA and the PMDA, the approval date was the date the EC and MHLW granted approval, respectively. The clinical datasets were those initially included in the submission, i.e., without any updates. For the post-marketing activities the overarching term “post-marketing measures” was used. This includes the “postmarked requirements,” “post-authorization measures” and “post-marketing investigations” as defined by the FDA, EMA and PMDA, respectively. The final date for data collections was 14 May 2021 and last check for tissue-agnostic approvals per agency was 1 October 2021.

Data Analysis

The submission and approval dates, clinical data packages, and the PMMs were descriptively compared between agencies. No statistics were used in this study.

RESULTS

Approvals per Regulatory Agency

Both the FDA and MHLW approved pembrolizumab for the treatment of patients with MSI-H or dMMR solid tumors (Figure 1). The application was first submitted to the FDA, with a difference of 571 days between submissions. The FDA granted “accelerated approval” and the MHLW granted “partial change approval.” Of note, on July, 2021 an extension of indication was applied for at the EMA for pembrolizumab as monotherapy in the treatment of unresectable or metastatic MSI-H or dMMR colorectal, endometrial, gastric, small intestine, biliary, or pancreatic cancer in adults who have received prior therapy (11). The review was ongoing at the final check for data availability (October 1, 2021). The FDA also approved pembrolizumab for the treatment of patients with Tumor Mutational Burden (TMB)-High solid tumors, i.e., a second tissue-agnostic indication for this medicinal product (12). However, no review documents were available for this approval at the final check for data availability.

The FDA and EC approved larotrectinib for the treatment of solid tumors that have a neurotrophic tyrosine receptor...
kinase (NTRK) gene fusion (Figure 1). The application was first submitted to the FDA, and the difference between submissions was 82 days. The FDA granted an “accelerated approval,” and the EC granted a “conditional marketing authorization.” On March 23, 2021, the MHLW approved larotrectinib, but no review documents were available at the final check for data availability (13). The FDA, EC and MHLW approved entrectinib for the treatment of solid tumors that have a NTRK gene fusion (Figure 1). The application was first submitted to the FDA but the difference between the submission dates was small – 21 days or less. The FDA granted an “accelerated approval,” the EC granted a “conditional marketing authorization” and the MHLW granted a “new approval.” Finally, on August 17, 2021, the FDA granted an “accelerated approval” for dostarlimab for the treatment of patients with dMMR recurrent or advanced solid tumors. Since only the FDA approved dostarlimab for a tissue-agnostic indication no comparison could be made between the three agencies. Therefore, dostarlimab was not included in our analysis.

Clinical Data Supporting the Submission
The FDA and PMDA approved pembrolizumab for MSI-H/dMMR solid tumors based on five and two clinical trials, respectively (Table 1). Data from KEYNOTE158 and KEYNOTE164 were submitted to both agencies, but different data cut-off dates were used. The most frequent tumor types included in the efficacy datasets were colorectal cancer and endometrial cancer (Supplementary Table 1). The application submitted to the FDA included pooled efficacy data from five clinical trials and pooled safety data from two trials, i.e., KEYNOTE016A and KEYNOTE164. The pooled efficacy population consisted of 149 patients. The primary endpoint was overall response rate (ORR). ORR was 35.6% (95% CI: 27.9, 43.8). The pooled safety population consisted of 145 patients. The updated efficacy data were August 7, 2016 and November 23, 2016 for KEYNOTE158 and August 3, 2016 and November 23, 2016 for KEYNOTE164. Updated safety data was also provided, but the safety review was based on the initial dataset. The application submitted to the PMDA included separately presented efficacy and safety data from KEYNOTE158 and KEYNOTE164. ORR was the primary endpoint in both studies. Response rates were 34.9% (95% CI: 24.8, 46.2) and 27.9% (95% CI: 17.1, 40.8), respectively.

The FDA and EMA approved larotrectinib for NTRK fusion-positive solid tumors on the basis of three clinical trials (Table 2). The most frequent tumor types included in the efficacy datasets were sarcoma and salivary gland (Supplementary Table 1). Both applications included pooled efficacy and safety data from the three clinical trials, but there were small differences in data cut-off dates and population sizes. The primary endpoint of the integrated analysis was ORR. The agencies focused their review on different analysis sets, which resulted in differently sized efficacy populations. The FDA focused on the primary analysis set (PAS), which consisted of the first 55 patients with NTRK fusion-positive solid tumors enrolled across the three studies. ORR was 75% (95% CI: 61, 85). The pooled safety population consisted of 144 patients from three studies. During the review, the FDA received updated efficacy and safety data. The updated clinical data cut-off date was February 19, 2018. The EMA initially focused their review on the PAS – same as the FDA – but considered the second extended PAS (ePAS2) to be the main analysis set. This analysis set consisted of 93 patients from the same clinical trials but was based on updated efficacy data. ORR in the ePAS2 was 72% (95% CI: 62, 81). The pooled safety dataset consisted of 176 patients from three studies. During the review, the EMA also received updated safety data. The updated clinical cut-off date was July 30, 2018.

The FDA and EMA approved entrectinib for NTRK fusion-positive solid tumors on the basis of four clinical trials, while the PMDA approved entrectinib for NTRK fusion-positive solid tumors on the basis of three clinical trials (Table 3).
### TABLE 1 | Clinical trials supporting the approval of pembrolizumab for the treatment of MSI-H/dMMR tumors.

| Name          | Design                          | Population                                | Dose                  | Primary endpoint | FDA          | PMDA          |
|---------------|---------------------------------|-------------------------------------------|-----------------------|------------------|--------------|---------------|
| KEYNOTE164    | Open-label, multicenter, Phase 2 trial | Previously treated patients with MSI-H CRC | 200 mg every 3 weeks | ORR              | 61           | 61           |
|               |                                 |                                           |                       |                  | June 3, 2016 | February 10, 2017 |
| KEYNOTE016A   | Investigator-initiated, open label, multi-center, 2-stage, Phase 2 trial | Previously treated patients with MSI-H CRC | 10 mg/kg every 2 weeks | ORR              | 28           | N.A.          |
|               |                                 |                                           |                       |                  | February 19, 2016 | N.A.          |
| KEYNOTE016C   | Investigator-initiated, open label, multi-center, 2-stage, Phase 2 trial | Previously treated patient with MSI-H non-CRC | 10 mg/kg every 2 weeks | ORR              | 30           | N.A.          |
|               |                                 |                                           |                       |                  | April 13, 2016 | N.A.          |
| KEYNOTE158    | Open-label, multicenter, multi-cohort, Phase 2 trial | Patients with advanced solid tumors evaluated for predictive biomarkers | 200 mg every 3 weeks | ORR              | 19           | 94           |
|               |                                 |                                           |                       |                  | June 17, 2016 | April 28, 2017 |
| KEYNOTE012    | Multicenter, multi-cohort trial | Patients with advanced solid tumors | 10 mg/kg every 2 weeks | ORR              | 6            | N.A.          |
|               |                                 |                                           |                       |                  | April 26, 2016 | N.A.          |
| KEYNOTE028    | Open-label, multicenter, multi-cohort, Phase 1b trial | Patients with PD-L1 positive advanced solid tumors | 10 mg/kg every 2 weeks | ORR              | 5            | N.A.          |
|               |                                 |                                           |                       |                  | June 20, 2016 | N.A.          |

CRC, colorectal cancer; FDA, Food and Drug Administration; MSI-H, microsatellite instability-high; N.A., not applicable; ORR, overall response rate; PD-L1, programmed cell death-1 ligand 1; PMDA, Pharmaceuticals and Medical Devices Agency.

most frequent tumor types included in the efficacy datasets were sarcoma and salivary gland (Supplementary Table 1). The applications submitted to the FDA and EMA included pooled efficacy and safety data from these clinical trials. The primary endpoint for the integrated efficacy analysis was ORR. The FDA and EMA focused on different analysis sets, which resulted in differently sized efficacy populations. The FDA focused on the PAS, which consisted of the first 54 patients enrolled in ALKA-372-001, RXDX-101-01, and RXDX-101-02. ORR was 57.4% (95% CI: 43.2, 70.8). The pooled safety population consisted of 355 patients from four studies. Updated efficacy and safety data was submitted. The updated clinical data cut-off date was October 31, 2018. The EMA initially focused on the PAS, but considered the extended PAS to be the main analysis set. This analysis set consisted of 74 patients from ALKA-372-001, RXDX-101-01, and RXDX-101-02, but was based on updated efficacy data. ORR in the extended PAS was 63.5% (95% CI: 51.5, 74.4). The pooled safety population consisted of 355 patients from four studies. During the review, the EMA also received updated efficacy data. The updated clinical data cut-off date was Oct 31, 2018. The application submitted to the PMDA included efficacy data from RXDX-101-02 and separately presented safety data from ALKA-372-001, RXDX-101-01, and RXDX-101-02. The PMDA focused on the PAS that consisted of 51 patients from study RXDX-101-02. The primary endpoint was ORR. Response rate was 56.9% (95% CI: 42.3, 70.7).

### Post-marketing Measures

The FDA imposed four PMMs and the PMDA imposed one PMM for pembrolizumab (Table 4 and Supplementary Table 2). Both agencies imposed a PMM to address the small sample size of patients with MSI-H/dMMR solid tumors other than colorectal cancer. To resolve this issue, the FDA requested the final study reports from KEYNOTE 158 and KEYNOTE 164. In contrast, the PMDA requested an use-result survey. The FDA imposed three other PMMs, which are related to safety in pediatric patients and use of companion diagnostics. The latter was not relevant to the PMDA review, as a companion diagnostic assay was approved in Japan on 10 September 2018.

The FDA imposed seven PMMs and the EMA imposed three PMMs for larotrectinib. Both agencies imposed a PMM.
# TABLE 2 | Clinical trials supporting the approval of larotrectinib for the treatment of NTRK tumors.

| Name          | Design                  | Population                                      | Dose                        | Primary endpoint                                                                 | FDA | EMA            | Data cut-off date | Number of patients | Data cut-off date   | Number of patients | Data cut-off date |
|---------------|-------------------------|-------------------------------------------------|------------------------------|---------------------------------------------------------------------------------|-----|----------------|-------------------|---------------------|-------------------|-------------------|-------------------|
| LOXO-TRK-14001 | Open-label, multicenter, Phase 1 Study | Adult patients with solid tumors | 50–400 mg/day QD or BID | Safety, MTD, RP2D | 66  | July 17, 2017  | 70                | February 19, 2018 |
| LOXO-TRK-15002 | Open-label, multicenter, Phase 2 Basket Study | Patients 12 years of age or older with NTRK fusion advanced cancer | 100 mg BID | BOR | 47  | July 17, 2017  | 63                | February 19, 2018 |
| LOXO-TRK-15003 | Open-label, Multicenter, Phase 1/2 Study | Pediatric patients with advanced solid or primary central nervous system tumors | Dosing based on adult equivalent of 100 or 150 mg BID, then 100 mg/m² BID (maximum of 100 mg BID) | Safety, DLT (part 1); ORR (part 2) | 31  | July 17, 2017  | 43                | February 19, 2018 |

BID, twice daily; BOR, best overall response; EMA, European Medicines Agency; FDA, Food and Drug Administration; MTD, maximum tolerated dose; NTRK, Neurotrophic Tyrosine Receptor Kinase; ORR, overall response rate; QD, once daily; RP2D, recommended phase 2 dose.

# TABLE 3 | Clinical trials supporting the approval of entrectinib for the treatment of NTRK tumors.

| Name          | Design                  | Population                                      | Primary endpoint                                                                 | FDA | PMDA | EMA            | Data cut-off date | Number of patients | Data cut-off date |
|---------------|-------------------------|-------------------------------------------------|---------------------------------------------------------------------------------|-----|------|----------------|-------------------|---------------------|-------------------|
| ALKA-371-001  | A dose escalation, Phase 1 study | Adult patients With Advanced/ Metastatic Solid Tumors | First cycle DLTs, MTD | 100–1,600 mg QD | 57  | 57             | 57                | May 31, 2018         |
| RXDX-101-01   | Open-label, multicenter, Phase 1 study | Adult patients with Locally Advanced or Metastatic Cancer | Dose escalation part; first cycle DLTs, MTD, and a biologically effective and RP2D Dose expansion part: ORR | 100–800 mg QD | 76  | 76             | 76                | May 31, 2018         |
| RXDX-101-02   | Open-label, multicenter, global Phase 2 Basket Study | Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | ORR | 600 mg QD | 206 | 206            | 206               | May 31, 2018         |
| RXDX-101-03   | Open-label, dose-escalation and expansion, Phase 1/1b study | Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions | MTD, RP2D | Dosing nomogram based on BSA, ranging from 250 mg/m² to 750 mg/m² | 16  | N.A.           | 16                | May 31, 2018         |

ALK, Anaplastic Lymphoma Kinase; BSA, body surface area; EMA, European Medicines Agency; FDA, Food and Drug Administration; MTD, maximum tolerated dose; N.A., not applicable; NTRK, Neurotrophic Tyrosine Receptor Kinase; ORR, overall response rate; QD, once daily; PMDA, Pharmaceuticals and Medical Devices Agency; ROS1, Proto-oncogene tyrosine-protein kinase 1; RP2D, recommended phase 2 dose.

to address the small sample size of patients with NTRK fusion-positive tumors in relation to the complexity of the tissue-agnostic indication (Table 5 and Supplementary Table 2). Both agencies requested a larger dataset from (ongoing) clinical trials to resolve this issue. Unique to the PMM imposed by the EMA is that it will address two additional issues, i.e., lack of prospectively studied cohorts and secondary NTRK mutations that cause resistance to larotrectinib. In addition, both agencies
imposed a PMM to address the limited safety data in pediatric patients, which resulted in comparable measures. The other PMMs were imposed by only one of the two agencies, and addressed issues related to: (1) duration of response (FDA only); (2) the dose in pediatric patients (EMA only); (3) the third dosage modification (FDA only); (4) moderate CYP inhibitors/inducers (FDA only); and (5) concomitant genetic mutations (EMA only). The underlying issues were not identified by the other agency or were not relevant for the review. The approval of a companion diagnostic was not required by the EMA, but it is indicated in the SmPC that a validated assay is required for patients with dMMR tumors. The approval of a companion diagnostic was already approved in Japan. The approval of a companion diagnostic was not a requirement by the EMA, but it is indicated in the SmPC that a validated assay is required for patients with MSI-H tumors.

**DISCUSSION**

This study was conducted to compare decision-making aspects of tissue-agnostic approvals between regulatory agencies. Specifically, we were interested in the PMMs imposed by the regulatory agencies to resolve outstanding issues related to the tissue-agnostic indication. At the time of our analysis, pembrolizumab, larotrectinib and entrectinib received regulatory approval for a tissue-agnostic indication. PMMs to address the risk of fractures (FDA, EMA), growth and development issues (FDA, PMDA, and EMA), and congestive heart failure (FDA, PMDA, EMA). The other PMMs were imposed by only one of the three agencies, and addressed issues related to: (1) the duration of response (FDA only); (2) off-target activity (FDA only); (3) dose in patients with hepatic impairment (FDA only); (4) companion diagnostics (FDA only); and (5) concomitant genetic mutations (EMA only). The underlying issues were not identified by the other agencies or were not relevant for the review. A companion diagnostic was already approved in Japan. The approval of a companion diagnostic was not a requirement by the EMA, but it is indicated in the SmPC that a validated assay is required for the selection of patients with NTRK gene fusion-positive solid tumors.

**TABLE 4 | Post-marketing measures for pembrolizumab for the treatment of MSI-H/dMMR tumors.**

| Agency       | Type of measure                                      | Short description of issue(s)                                                                 | Short description of measure                                                                 | Planned sample size | Due date       |
|--------------|------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|---------------------|----------------|
| FDA          | Accelerated approval requirements                    | Limited experience with treatment of patients with MSI-H/dMMR tumors other than metastatic colorectal cancer and endometrial cancer | Submit the final report, including datasets, from trials conducted to verify and describe the clinical benefit of pembrolizumab in patients with MSI-H/dMMR tumors | ≥124 patients (KEYNOTE164); ≥300 patients (KEYNOTE158) | March, 2023 |
| Postmarketing requirements under 505(o)         | Limited experience of pembrolizumab in children with congenital mismatch repair deficiency syndromes    | Conduct a trial to determine an adequately safe dosage regimen in children with MSI-H/dMMR primary central nervous system malignancies | Unspecified or not applicable                                                                 | March, 2023          |
| Postmarketing commitments subject to reporting requirements under section 506B | There remains uncertainty regarding the performance characteristics across all laboratories which may be performing tests for determination of MSI-H and dMMR tumor status | Commitment to support the availability of an in vitro diagnostic device that is essential to the safe and effective use of pembrolizumab for patients with dMMR tumors | Unspecified or not applicable                                                                 | June, 2019           |
| Postmarketing commitments subject to reporting requirements under section 506B | There remains uncertainty regarding the performance characteristics across all laboratories which may be performing tests for determination of MSI-H and dMMR tumor status | Commitment to support the availability of an in vitro diagnostic device that is essential to the safe and effective use of pembrolizumab for patients with MSI-H tumors | Unspecified or not applicable                                                                 | June, 2019           |
| PMDA         | Post marketing surveillance                          | Limited data is available as to the efficacy of pembrolizumab in the treatment of MSI-H tumors (except colorectal cancer) | A drug use-results survey to collect information on the characteristics of patients treated with pembrolizumab, to promptly collect data on the efficacy and safety of pembrolizumab, and to take necessary actions to ensure the proper use of pembrolizumab. | ≥30 patients        | Not specified |

* dMMR,Mismatch repair deficient; FDA, Food and Drug Administration; MSI-H, microsatellite instability-high; PMDA, Pharmaceuticals and Medical Devices Agency.
### TABLE 5 | Post-marketing measures for larotrectinib for the treatment of NTRK tumors.

| Agency | Type of measure | Short description of issue(s) | Short description of measure | Planned sample size | Due date |
|--------|----------------|-------------------------------|------------------------------|---------------------|----------|
| FDA    | Accelerated approval requirements | Due to the small sample size, there is an uncertainty regarding the magnitude of the treatment effect of larotrectinib in any single histologic subtype of solid tumors with an activating NTRK fusion | Submit the final report, including datasets, from ongoing and proposed trials conducted to verify and describe the clinical benefit of larotrectinib | Unspecified or not applicable | August, 2025 |
|        | Accelerated approval requirements | Not described/ The median DOR had not been reached as of the February 19, 2018 data cut-off date. | Submit the final report, including datasets, from the first 55 patients with NTRK fusion solid tumors to further characterize the duration of response in patients who achieved a complete or partial response to larotrectinib | 55 patients | March, 2020 |
|Postmarketing Requirements under 505 (o) | | The number of pediatric patients in the safety database was small and there are inherent limitations in interpreting longitudinal growth and development information in single arm trials | Conduct a study in pediatric patients with NTRK-fusion solid tumors to evaluate the potential serious risk of adverse long-term effects of larotrectinib on the growth and development | Unspecified or not applicable | August, 2028 |
|Postmarketing Requirements under 505 (o) | Limited clinical experience with a third dose modification | Conduct a study in adult or pediatric patients with a body surface area of at least 1.0 m² who experienced an adverse reaction requiring a third dosage modification of larotrectinib to better characterize the tolerability of this dosage modification | Unspecified or not applicable | August, 2028 |
|Postmarketing Requirements under 505 (o) | The effects of moderate and weak CYP3A4 inhibitors on the PK of larotrectinib have not been studied | Conduct a physiologically-based pharmacokinetic modeling study to evaluate the effect of a moderate CYP3A4 inhibitor on the pharmacokinetics of larotrectinib | Unspecified or not applicable | September, 2019 |
|Postmarketing commitments subject to reporting requirements under section 506B | The effects of CYP3A moderate and weak inducers on the pharmacokinetics of larotrectinib have not been studied | Conduct a physiologically-based pharmacokinetic modeling study to evaluate the effect a moderate CYP3A4 inducer on the pharmacokinetics of larotrectinib | Unspecified or not applicable | September, 2019 |
|Postmarketing commitments subject to reporting requirements under section 506B | Several challenges remain for NTRK fusion testing | Conduct an analytical and clinical validation study that is adequate to support labeling of an in vitro diagnostic device that is essential to the safe and effective use of larotrectinib | Unspecified or not applicable | July, 2021 |
|EMA    | Specific Obligations | 1) The small efficacy data base raises issues with regard to the representativeness in relation to the indication sought, encompassing any solid tumor type; 2) The application is lacking in prospectively studied cohorts that could provide an unbiased estimate of ORR; and 3) Secondary NTRK mutations altering the kinase domain of TRK thus appear to be a major acquired resistance mechanism to larotrectinib | In order to further confirm the histology-independent efficacy of larotrectinib and to investigate the primary and secondary resistance mechanisms, the MAH should submit a pooled analysis for the increased sample size including the final report of study LOXO-TRK-15002 | 200 patients (LOXO-TRK-15002 and LOXO-TRK-15003) | June 30, 2024 |
|        | Specific Obligations | The long-term safety follow-up is limited and neurodevelopment in pediatric patients is a concern based on preclinical data. | In order to further investigate the long-term toxicity and developmental effects of larotrectinib in pediatric patients the MAH should submit the final report of study | Unspecified or not applicable | March 31, 2027 |

(Continued)
agnostic indication(s) by most, or all three, regulatory agencies. Datasets supporting the approvals were generally small, especially for the two TRK inhibitors. Numerous PMMs were imposed by the agencies, and these were mostly imposed to address issues related to efficacy, safety, and pharmacokinetics.

There remain uncertainties concerning the treatment effect across tumor types for medicinal products for tissue-agnostic indications. Our data shows that all three agencies will receive additional data to further confirm the tissue-agnostic indication in the post-marketing setting. Larger datasets will be collected from (ongoing) clinical trials or real-world studies. These studies shall include patients with tumor types that were underrepresented in the initial datasets. However, both approaches to collect data in the post-marketing setting, i.e., clinical trials vs. real-world studies, have their inherent challenges and/or limitations. For example, clinical trials may have stringent eligibility criteria, which result in limited generalizability of the study results (14). While generalization may be improved with real-world studies, these studies are not without challenges either, which can be of operational, technical and/or methodological nature (15). For instance, the quality and completeness of information is critical to describe the patients characteristics and treatment effects (16). There is currently limited guidance available on the data requirements to confirm a tissue-agnostic indication in the post-marketing setting. In the guideline of the PMDA it is recommended that high quality data, including data from cancer types not evaluated in the clinical trials, is required after marketing authorization (9). For future applications, a global strategy toward the generation of data in the post-marketing setting may be of interest, dependent on emerging insights from the current approaches.

As the FDA and EC granted expedited approval, i.e., "accelerated approval" and "conditional marketing authorization," respectively, the drug developers are obligated to provide confirmatory data in the post-marketing setting. Importantly, regulatory action can be taken if new data alters the benefit-risk ratio, which might also impact the tissue-agnostic indication. Randomized-controlled trials remain the gold standard to determine the efficacy and safety of a medicinal product and are often preferred as confirmatory trials. However, as addressed by the FDA reviewers, it will be challenging to conduct a randomized-controlled trial in the tissue-agnostic setting (17). Some biomarker-tumor combinations are extremely rare (18). The low prevalence of a biological characteristic may lead to recruitment challenges, even for basket trials (19). In addition, shared among medicinal products approved for a tissue-agnostic indication is the "strong scientific rationale" (20). Such a scientific/biological rationale and the demonstration of large treatment effects may bring clinical equipoise into question. This explains why confirmatory data for the tissue-agnostic approvals will be obtained from ongoing single-arm (basket) trials or real-worlds studies. Recently, Seligson el al. reflected on tissue-agnostic approvals by the FDA and suggested that real-world data can be used as an alternative strategy to confirm benefit (20). Miksad et al. described that the identification of real-world patients could expand the evidence base for the NTRK population (16). Real-world data might also provide a more comprehensive understanding of long-term effects for drugs approved on the basis of earlier phase clinical trials, i.e., phase 1 or phase 2 trials (21). More general, it has been published that post-marketing studies are sometimes delayed (22). Regardless of PMM, it is important that regulators insist that the due date for these (mandatory) measures will be met, as the confirmation of benefit is an important aspect of tissue-agnostic approvals.

The first approvals set precedent for the level of evidence necessary to register medicinal products for a tissue-agnostic indication. Our results show that tissues-agnostic approvals are supported by somewhat small (efficacy) datasets – albeit sufficient for the initial assessment of the benefit-risk balance, especially considering the complexity of a tissue-agnostic indication. Furthermore, agencies have a different approach toward reviewing the submitted data, i.e., some agencies accept integrated datasets, focus on particular analysis sets and/or request updated data. Findings from literature confirm that the size of the efficacy populations supporting the tissue-agnostic approvals can be considered smaller than generally observed for registration. For example, Tenhunen et al. reported that the

| Agency | Type of measure | Short description of issue(s) | Short description of measure | Planned sample size | Due date |
|--------|----------------|-------------------------------|-----------------------------|---------------------|----------|
| Specific Obligations | There is uncertainty in the predicted exposure in the smallest children (< 6 years of age) due to few patients included in each age group | LOXO-TRK-15003 including 5 year follow up data | In order to further confirm the appropriate dose recommended in pediatric patients, the MAH should submit an updated pop PK model based on additional PK sampling in patients aged 1 month to 6 years from study LOXO-TRK-15003 | Unspecified or not applicable | September 30, 2021 |

CYP3A4, cytochrome P450 3A4; DOR, duration of response; EMA, European Medicines Agencies; FDA, Food and Drug Administration; PK, pharmacokinetics; MAH, marketing authorization holder; NTRK, neurotrophic tyrosine receptor kinase; ORR, overall response rate.
### TABLE 6 | Post-marketing measures for entrectinib for the treatment of NTRK tumors.

| Agency | Type of measure | Short description of issue(s) | Short description of measure | Planned sample size | Due date |
|--------|----------------|-------------------------------|-------------------------------|---------------------|----------|
| FDA    | Accelerated approval requirements | Not specified | Submit the final report, including datasets, from the first 54 patients with NTRK-fusion solid tumors enrolled across ALKA-372-001, RXDX-101-01, and RXDX-101-02 to verify and describe the clinical benefit and further characterize the duration of response in patients who achieved a complete or partial response to entrectinib. | 54 patients | June, 2021 |
|        | Accelerated approval requirements | Due to the small sample size, there is a degree of uncertainty regarding the magnitude of the treatment effect of entrectinib in any single histologic subtype of solid tumors with an activating NTRK fusion | | Unspecified or not applicable | March, 2027 |
|        | Postmarketing requirements under 505(o) | Entrectinib had potential activity against other receptors that could contribute to CNS effects | Determine functional activation or inhibition of off-target receptors, transporters, and/or channels that, at concentrations of 10 µM, showed >50% inhibition by entrectinib or M5 in the secondary pharmacology studies. | Unspecified or not applicable | September, 2020 |
|        | Postmarketing requirements under 505(o) | Congestive heart failure events were reported in 12 (3.4%) patients, including Grade 3 (2.3%) | Submit integrated safety analyses and supporting data from patients enrolled in clinical trial(s) designed to characterize the cardiac risks and its sequelae in patients exposed to entrectinib with reasonable precision | Unspecified or not applicable | June, 2022 |
|        | Postmarketing requirements under 505(o) | The small number of pediatric patients in the safety database, the limited duration of follow-up, and limitations inherent in interpreting longitudinal growth and development information in single arm trials | Conduct clinical trial(s) of entrectinib in pediatric patients 12 years of age and older with NTRK-fusion solid tumors to evaluate the potential serious risk of adverse long-term effects of entrectinib on growth and development | Unspecified or not applicable | August, 2029 |
|        | Postmarketing requirements under 505(o) | Seventeen (6%) adult patients and 7 (23%) pediatric patients experienced fractures | Submit integrated safety analyses and supporting data from patients enrolled in clinical trial(s) designed to characterize the risk of fractures and its sequelae in patients exposed to entrectinib with reasonable precision | Unspecified or not applicable | March, 2025 |
|        | Postmarketing requirements under 505(o) | There is no pharmacokinetic data to recommend entrectinib dose for patients with moderate and severe hepatic impairment. | Complete a pharmacokinetic trial to evaluate the effect of moderate and severe hepatic impairment on the pharmacokinetics and safety of Rozlytrek (entrectinib) compared to subjects with normal hepatic function | Unspecified or not applicable | December, 2021 |
|        | Postmarketing commitments subject to reporting requirements under section 506B | Several challenges remain for NTRK fusion testing | Commit to providing adequate analytical and clinical validation results from clinical trial data to support labeling of the F1CDx test to detect NTRK rearrangements for identifying patients who may benefit from entrectinib | Unspecified or not applicable | December, 2019 |
| EMA    | Specific Obligation | 1) The estimates by tumor types are not robust due to the small sample sizes of individual subgroups and the limited number of tumor types; and 2) The available safety data in the pediatric setting is limited | In order to further confirm the histology-independent efficacy of entrectinib in adult and pediatric patients, the MAH should submit a pooled analysis for an increased sample size of NTRK fusion-positive patients from RXDX-101-02, RXDX-101-03 and any additional clinical trial conducted according to an agreed protocol | 200 patients | March 31, 2027 |

*(Continued)*
TABLE 6 | Continued

| Agency | Type of measure | Short description of measure | Planned sample size | Due date |
|--------|-----------------|-----------------------------|--------------------|---------|
| PMDA   | Post-marketing surveillance | Investigate delayed growth and development in pediatric patients in clinical practice | Not specified | Not specified |

To conduct a post-marketing use-results survey to investigate delayed growth and development in pediatric patients in clinical practice.

The safety information from patients treated with entrectinib, including Japanese patients, is limited, and the number of patients with NTRK fusion-positive, advanced/recurrent solid tumors (patients eligible for entrectinib therapy) is extremely limited.

In order to further investigate the impact of the presence/absence of other molecular alteration on the efficacy of entrectinib, a delayed post-marketing surveillance, to promptly collect data on the safety and efficacy of entrectinib, to investigate the impact of the presence/absence of other molecular alteration on the efficacy of entrectinib, and to take necessary measures to ensure proper use of entrectinib.

| Agency | Type of measure | Short description of measure | Planned sample size | Due date |
|--------|-----------------|-----------------------------|--------------------|---------|
| FDA    | Post-marketing surveillance | Investigate delayed growth and development in pediatric patients in clinical practice | Not specified | Not specified |

**Median number of patients in the target population was 175 for EC approvals based on results from single-arm trials (23). This is substantially larger than the initial efficacy population supporting the approval of the TRK inhibitors. The current tissue-agnostic approvals were based on a strong biological rationale and thereby the expectation of consistency in treatment effect across tumor types (20). The importance of a strong biological rationale to support a tissue-agnostic approach is highlighted in the EMA draft guidance document. It is specified in this guidance document that the assessment of homogeneity can be conducted only if a sufficient number of patients is included in the study, which is not always feasible (8). The PMMs will allow re-assessment of homogeneity based on a larger dataset in the post-marketing setting, sometimes including data from at least 200 additional patients, based on our findings. Regarding the integrated analysis sets, Seligson et al. reported that the FDA accepted pooled data due to the consistent anti-tumor activity across trials (20). However, not every agency might accept this strategy. For instance, the PMDA considered RXDX-101-02 to be the sole pivotal study to support the application of entrectinib and focused its review on the NTRK fusion-positive cohort (24). Early dialogue between developers and regulators to discuss (clinical) development plans may prevent regulatory hurdles.**

Our results show that not all developers submitted an application to all agencies at the same time. The differences in submission date for pembrolizumab are the most noticeable. For instance, only recently an extension of indication for six MSI-h tumors for pembrolizumab was submitted to the EMA (11). Remarkably, the developer did not apply for a tissue-agnostic indication in the European Union (EU) (25); a different strategy compared to the applications submitted to FDA and PMDA. Understanding why the developer did not seeking a tissue-Indication is of interest, but can only be speculated on. Likewise, while the EC approved dostarlimab for the treatment of patients with dMMR/MSI-H recurrent or advanced endometrial cancer, the applicant did not apply for a tissue-agnostic indication in the EU (26). A delay in submission is one of the factors that may contribute to disparity in approved therapies between countries or continents. In the absence of regulatory approval, patients in Europe are often dependent of available information is sufficiently abundant to compare at least some aspects related to decision-making for tissue-agnostic approvals.
CONCLUSION

The current approvals set precedent for the level of evidence necessary to register medicinal products for tissue-agnostic indication. A strong biological rationale and consistency in treatment effect across tumor types may allow for (expedited) approval, but confirmation of benefit in the post-marketing setting remains an important aspect of the tissue-agnostic approvals. There are different approaches to further confirm the tissue-agnostic indication in the post-marketing setting, albeit these are not without inherent limitations. These approaches to collect post-marketing data could complement existing data packages, but it will be of importance that “new” data are of high quality. For future applications, a global strategy toward data generation post-marketing may be of interest, dependent on emerging insights from the current approaches. Eventually, only the post-marketing data will continue to shed light on the appropriateness of the tissue-agnostic indication.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

JM, AP, VS-B, and AB designed the study. JM and OS performed the research. JM, OS, AP, and VS-B analyzed the data. JM, OS, PH, EV, AP, VS-B, and AB wrote the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.893400/full#supplementary-material

REFERENCES

1. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. (2019) 25:3753–8. doi: 10.1158/1078-0432.CCR-18-4070
2. Food and Drug Administration. FDA Approves Pembrolizumab for Adults and Children with TMB-H Solid Tumors. Available online at: https://www.fda.gov/drugs/drugs-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (accessed March 3, 2022).
3. Food and Drug Administration. FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions. Available online at: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions (accessed March 3, 2022).
4. Food and Drug Administration. FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC. Available online at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc (accessed March 3, 2022).
5. Food and Drug Administration. FDA Grants Accelerated Approval to Dostarlimab-gly1 for dMMR Advanced Solid Tumors. Available online at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gly1-dmmr-advanced-solid-tumors (accessed April 30, 2022).
6. U.S. Food and Drug administration. Expedited Programs for Serious Conditions – Drugs and Biologics. (2014). Available online at: https://www.fda.gov/files/drugs/published/Expedited-Programs-for-Serious-Conditions-Drugs-and-Biologics.pdf (accessed March 3, 2022).
7. European Medicines Agency. Guideline on the Scientific Application and the Practical Arrangements Necessary to Implement Commission Regulation (EC) No 507/2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use Falling Within the Scope of Regulation (EC) No 726/2004. (2016). Available online at: https://www.emea.europa.eu/en/documents/scientific-guideline/scientific-application-practical-arrangements-necessary-implement-commission-regulation-ec-2006/conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf (accessed March 3, 2022).
8. European Medicine Agency. Draft Guideline on the Clinical Evaluation of Anticancer Medicinal Products. Rev 6. Available online at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-6_en.pdf (accessed March 3, 2022).
9. Minami H, Kiyota N, Kimbara S, Ando Y, Shimokata T, Ohtsu A, et al. Guidelines for clinical evaluation of anti-cancer drugs. Cancer Sci. (2021) 112:2563–77. doi: 10.1111/cas.14967
10. U.S. Food and Drug Administration. Guidance for industry. Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease. (2018). Available online at: https://www.fda.gov/media/117173/download (accessed March 3, 2022).
11. Horizonscan Geneesmiddelen. Pembrolizumab. (2021). Available online at: https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/pembrolizumab-oncologie-en-hematologie-oncologie_overig%5BS%5D-versie (accessed March 3, 2022).
12. U.S. Food and Drug Administration. Pembrolizumab Label. (2021). Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s112lbr.pdf (accessed March 3, 2022).
13. Bayer. Bayer Receives Approval for Vitrakvi™ in Japan. Available online at: https://media.bayer.com/baynews/baynews.nsf/id/f082D994FC24A468C12586A1003517D1open&ref=irrefndcd (accessed March 3, 2022).
14. Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. (2019) 16:312–25. doi: 10.1038/s41571-019-0167-7
15. Cava A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. (2019) 106:36–9. doi: 10.1002/cpt.1426
16. Miksad RA, Samant MK, Sarkar S, Abernethy AP. Small but mighty: the use of real-world evidence to inform precision medicine. Clin Pharmacol Ther. (2019) 106:87–90. doi: 10.1002/cpt.1466
17. Center for Drug Evaluation and Research. Rozlytrek Multi-Discipline Review. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/12725Orig1s000%2012726Orig1s000MultidisciplineR.pdf (accessed March 3, 2022).
18. Flaherty KT, Le DT, Lemery S. Tissue-agnostic drug development. Am Soc Clin Oncol Educ Book. (2017) 37:222–30. doi: 10.1200/EDBK_173855
19. Park JHJ, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. Ca Cancer J Clin. (2020) 70:125–37. doi: 10.3322/caac.21600
20. Seligson ND, Knepper TC, Ragg S, Walko CM. Developing drugs for tissue-agnostic indication: a paradigm shift in leveraging cancer biology for precision medicine. Clin Pharmacol Ther. (2021) 109:334–42. doi: 10.1002/cpt.1946
21. Blumenthal GM, Kleutz PG, Schneider J, Goldberg KB, McKee AE, Pazdur R. Oncology drug approvals: evaluating endpoints and
evidence in an era of breakthrough therapies. *Oncologist.* (2017) 22:762–7. doi: 10.1634/theoncologist.2017-0152

22. Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. *N Engl J Med.* (2017) 377:1114–7. doi: 10.1056/NEJMmp1705800

23. Tenhunen O, Lasch F, Schiel A, Turpeinen M. Single-arm clinical trials as pivotal evidence for cancer drug approval: a retrospective cohort study of centralized European marketing authorizations between 2010 and 2019. *Clin Pharmacol Ther.* (2020) 108:653–60. doi: 10.1002/cpt.1965

24. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. *Rozlytrek Report on the Deliberation Result.* Available online at: https://www.pmda.go.jp/files/000232794.pdf (accessed March 3, 2022).

25. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Minutes for the Meeting on 11-14 October 2021. Available online at: https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-11-14-october-2021_en.pdf (accessed March 3, 2022).

26. European Medicines Agency. Assessment Report Jemperli. Available online at: https://www.ema.europa.eu/en/documents/assessment-report/jemperli-epar-public-assessment-report_en.pdf (accessed April 28, 2022).

27. Kok M, Chalabi M, Haanen J. How I treat MSI cancers with advanced disease. *ESMO Open.* (2019) 4:e000511. doi: 10.1136/esmoopen-2019-000511

28. van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S Hoes LR et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. *Ann Oncol.* (2019) 30:663–4. doi: 10.1093/annonc/mdz119

**Author Disclaimer:** The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of, or reflecting the position of the EMA or one of its committees, working parties, or any of the national agencies.

**Conflict of Interest:** EV initiated and led the DRUP as one of the principal investigators.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Mulder, van Stuijvenberg, van Hennik, Voest, Pasmooij, Stoyanova-Beninska and de Boer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.